Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium

J Hepatol. 2021 Jan;74(1):200-219. doi: 10.1016/j.jhep.2020.08.009. Epub 2020 Sep 5.

Abstract

Management of decompensated cirrhosis is currently geared towards the treatment of complications once they occur. To date there is no established disease-modifying therapy aimed at halting progression of the disease and preventing the development of complications in patients with decompensated cirrhosis. The design of clinical trials to investigate new therapies for patients with decompensated cirrhosis is complex. The population of patients with decompensated cirrhosis is heterogeneous (i.e., different etiologies, comorbidities and disease severity), leading to the inclusion of diverse populations in clinical trials. In addition, primary endpoints selected for trials that include patients with decompensated cirrhosis are not homogeneous and at times may not be appropriate. This leads to difficulties in comparing results obtained from different trials. Against this background, the LiverHope Consortium organized a meeting of experts, the goal of which was to develop recommendations for the design of clinical trials and to define appropriate endpoints, both for trials aimed at modifying the natural history and preventing progression of decompensated cirrhosis, as well as for trials aimed at managing the individual complications of cirrhosis.

Keywords: ACLF; AKI; Ascites; Cirrhosis; Clinical trials; Endpoints; Hepatic encephalopathy; Hyponatremia; Infections; Liver transplant; Quality of life.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Ascites* / etiology
  • Ascites* / therapy
  • Clinical Trials as Topic
  • Consensus
  • Disease Management
  • Disease Progression
  • Endpoint Determination
  • Europa
  • Hepatic Encephalopathy* / etiology
  • Hepatic Encephalopathy* / therapy
  • Humans
  • Hypertension, Portal* / etiology
  • Hypertension, Portal* / therapy
  • Liver Cirrhosis* / complications
  • Liver Cirrhosis* / physiopathology
  • Liver Cirrhosis* / psychology
  • Liver Cirrhosis* / therapy
  • Quality of Life*
  • Research Design
  • Secondary Prevention / methods*
  • Severity of Illness Index